Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

regulatory decisions

- PMLiVE

Santhera’s Raxone turned down for rare eye condition

EMA concerned about drug's ability to improve eyesight

- PMLiVE

EMA recommends approval for alcohol dependency drug

Lundbeck’s Selincro to be used in conjunction with psychosocial support

Sanofi reception

Blow for Sanofi as EMA turns down cholesterol drug Kynamro

Points to safety concerns related to liver toxicity and cardiovascular events

- PMLiVE

Roche’s Perjeta backed in EU for breast cancer

CHMP recommends use alongside Herceptin

Novartis building

CHMP backs Novartis’ Bexsero, Exjade

European recommendations for meningitis vaccine and thalassaemia treatment

Sanofi reception

Sanofi’s Lyxumia and Zaltrap backed for European approval

Company on course to expand its diabetes and cancer portfolio

- PMLiVE

Vivus fails to get European backing for obesity treatment Qsiva

EMA raises concerns about drug’s cardiovascular safety

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

Dr Ian Hudson elected vice chair of CHMP

Will serve a three-year term on EMA's scientific advisory committee

Almirall’s IBS drug Constella backed by CHMP

On track to become the first drug specifically approved for the condition

- PMLiVE

Vivus expects knockback from EMA for obesity drug

Setback comes despite US approval for Qsiva/Qsymia

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links